PTD-DBM
Also known as: Protein transduction domain–DBM, CXXC5 inhibitor peptide
PTD-DBM (also called Protein transduction domain–DBM or CXXC5 inhibitor peptide) is a hair-follicle Wnt research peptide. PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif.
For research use only.
Key Facts
- CAS
- 1609454-11-6
- Molecular Weight (MW)
- 3082.6 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Administration Route
- Topical
- Frequency
- Research-dependent
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- CXXC5–Dvl interactionWnt pathway
Research summary
Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
Peptide Library's PTD-DBM profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Topical research formulations in published mouse work
- Frequency
- Research-dependent
- Cycle
- —
- Administration Route
- Topical
- Reconstitution Guide
- —
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Molecular formula | C124H225N61O28S2 |
|---|---|
| Molecular weight | 3082.6 g/mol |
| CAS number | 1609454-11-6 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 176453931 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif. It targets CXXC5, a negative regulator of Wnt signalling that binds Dishevelled and prevents it from transducing the Wnt signal. By competitively disrupting the CXXC5-Dishevelled interaction, the peptide relieves that inhibition and allows beta-catenin to accumulate and drive transcription. Because Wnt/beta-catenin signalling controls the transition of hair follicles from telogen into anagen, this was investigated for hair growth, and mouse studies report anagen induction, particularly when combined with valproic acid. Evidence is preclinical with no human trials.
Origin
Synthetic protein-transduction-domain peptide.
Targets
Studies
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2)
- Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing
Regulatory & research status
PTD-DBM is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Potential Side Effects
Side Effects
- Unknown human safety
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PTD-DBM: frequently asked questions
What is PTD-DBM?
Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
How does PTD-DBM work?
PTD-DBM is a fusion of a protein transduction domain, which carries the molecule across cell membranes, with a peptide derived from the Dishevelled-binding motif. It targets CXXC5, a negative regulator of Wnt signalling that binds Dishevelled and prevents it from transducing the Wnt signal.
Is PTD-DBM FDA approved?
No. PTD-DBM is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to PTD-DBM?
Compounds most often compared with PTD-DBM include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies — Cells, 2025External reference
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2) — Cells, 2023External reference
- Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment — Adv Healthc Mater, 2023External reference
- The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing — J Exp Med, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This PTD-DBM profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PTD-DBM research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →